·3 min read
Biotech Intelligence #10: The GLP-1 Race Goes East — Chinese Companies Enter the $100B Obesity Market
AstraZeneca's $18.5B CSPC deal wasn't just a cardiovascular play — it signaled Big Pharma's recognition that Chinese small molecule innovation extends to metabolic disease. We map the emerging Chinese GLP-1 landscape and analyze what it means for the global obesity drug race.
MetabolicSmall MoleculeAstraZenecaLicensingCDE Filing